Posted by Michael Wonder on 23 Oct 2023
NervGen Pharma receives fast track designation for NVG-291 for the treatment of individuals with spinal cord injury
23 October 2023 - NervGen Pharma today announced that the US FDA has granted fast track designation for its proprietary lead compound, NVG-291, in individuals with spinal cord injury.
NVG-291 is derived from the intracellular wedge domain of the receptor type protein tyrosine phosphatase sigma.
